263 related articles for article (PubMed ID: 8833961)
21. Relationship between HPLC precision and number of significant figures when reporting impurities and when setting specifications.
Agut C; Segalini A; Bauer M; Boccardi G
J Pharm Biomed Anal; 2006 May; 41(2):442-8. PubMed ID: 16472956
[TBL] [Abstract][Full Text] [Related]
22. Applications of hyphenated LC-MS techniques in pharmaceutical analysis.
Ermer J; Vogel M
Biomed Chromatogr; 2000 Oct; 14(6):373-83. PubMed ID: 11002275
[TBL] [Abstract][Full Text] [Related]
23. Quantitative NMR spectroscopy--applications in drug analysis.
Holzgrabe U; Deubner R; Schollmayer C; Waibel B
J Pharm Biomed Anal; 2005 Aug; 38(5):806-12. PubMed ID: 15893899
[TBL] [Abstract][Full Text] [Related]
24. A quality evaluation strategy for multi-sourced active pharmaceutical ingredient (API) starting materials.
Gavin PF; Olsen BA; Wirth DD; Lorenz KT
J Pharm Biomed Anal; 2006 Jun; 41(4):1251-9. PubMed ID: 16621411
[TBL] [Abstract][Full Text] [Related]
25. Finding key impurities in different manufacturing routes of a drug substance using liquid chromatography/mass spectrometry followed by principal components analysis.
Carrier D; Eckers C; Arnoult T; Thurston T; Major H
Rapid Commun Mass Spectrom; 2007; 21(23):3946-8. PubMed ID: 17975854
[No Abstract] [Full Text] [Related]
26. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
27. Analytical advances in pharmaceutical impurity profiling.
Holm R; Elder DP
Eur J Pharm Sci; 2016 May; 87():118-35. PubMed ID: 26690047
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
[TBL] [Abstract][Full Text] [Related]
29. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs).
Elder DP; Teasdale A; Lipczynski AM
J Pharm Biomed Anal; 2008 Jan; 46(1):1-8. PubMed ID: 18053672
[TBL] [Abstract][Full Text] [Related]
30. Analytical approaches for the detection of epoxides and hydroperoxides in active pharmaceutical ingredients, drug products and herbals.
Elder DP; Snodin D; Teasdale A
J Pharm Biomed Anal; 2010 Apr; 51(5):1015-23. PubMed ID: 20031361
[TBL] [Abstract][Full Text] [Related]
31. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
32. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
[TBL] [Abstract][Full Text] [Related]
33. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
[TBL] [Abstract][Full Text] [Related]
34. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
Pokar D; Rajput N; Sengupta P
Int J Pharm; 2020 Feb; 576():119018. PubMed ID: 31911117
[TBL] [Abstract][Full Text] [Related]
35. Elemental Impurities in Pharmaceutical Excipients.
Li G; Schoneker D; Ulman KL; Sturm JJ; Thackery LM; Kauffman JF
J Pharm Sci; 2015 Dec; 104(12):4197-4206. PubMed ID: 26398581
[TBL] [Abstract][Full Text] [Related]
36. Pharmaceutical impurities: analytical, toxicological and regulatory perspectives.
Basak AK; Raw AS; Yu LX
Adv Drug Deliv Rev; 2007 Jan; 59(1):1-2. PubMed ID: 17196297
[No Abstract] [Full Text] [Related]
37. An overview of recent applications of inductively coupled plasma-mass spectrometry (ICP-MS) in determination of inorganic impurities in drugs and pharmaceuticals.
Nageswara Rao R; Talluri MV
J Pharm Biomed Anal; 2007 Jan; 43(1):1-13. PubMed ID: 16891084
[TBL] [Abstract][Full Text] [Related]
38. Immunochemical binding assays for detection and quantification of trace impurities in biotechnological production.
Mattiasson B; Teeparuksapun K; Hedström M
Trends Biotechnol; 2010 Jan; 28(1):20-7. PubMed ID: 19896744
[TBL] [Abstract][Full Text] [Related]
39. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
[TBL] [Abstract][Full Text] [Related]
40. Drug safety, drug quality, drug analysis.
Görög S
J Pharm Biomed Anal; 2008 Sep; 48(2):247-53. PubMed ID: 18082992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
